mRNA‐1273 – ModernaTX leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).
mRNA‐1273 – ModernaTX showed no clear difference in serious adverse eventsl compared with placebo (moderate certainty).
mRNA‐1273 – ModernaTX leads to higher local reactogenicity eventsi compared with placebo (high certainty).
The review found no eligible studies for this question.
It is very uncertain whether CVnCoV – CureVac AG changes all‐cause mortalityh compared with placebo (very low certainty).
CVnCoV – CureVac AG leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).
CVnCoV – CureVac AG probably leads to higher any adverse eventj compared with placebo (moderate certainty).
CVnCoV – CureVac AG showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
CVnCoV – CureVac AG leads to higher local reactogenicity eventsi compared with placebo (high certainty).
The review found no eligible studies for this question.
ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).
ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher systemic reactogenicity eventsi compared with placebo (moderate certainty).